КЛИНИКО-МОРФОЛОГИЧЕСКИЕ И МОЛЕКУЛЯРНО-БИОЛОГИЧЕСКИЕ ФАКТОРЫ ПРОГНОЗА РЕДКИХ ФОРМ РАКА ТЕЛА МАТКИ
https://doi.org/10.17650/1994-4098-2008-0-2-60-69
Аннотация
КЛИНИКО-МОРФОЛОГИЧЕСКИЕ И МОЛЕКУЛЯРНО-БИОЛОГИЧЕСКИЕ ФАКТОРЫ ПРОГНОЗА РЕДКИХ ФОРМ РАКА ТЕЛА МАТКИ
Об авторах
К. П. ЛактионовРоссия
Г. М. Абдуллаева
Россия
О. А. Анурова
Россия
Список литературы
1. Lauchlan S.C. Tubal (serous) carcino- ma of the endometrium. Arch Pathol Lab Med 1981;105:615—8.
2. Hendrickson M., Ross J., Eifel P.J. Adenocarcinoma of the endometium: analysis of 256 cases with carcinoma lim- ited to the uterine corpus. Gynecol Oncol 1982;13:373—92.
3. Trope C., Kristensen G.B., Abeler V.M. Clear-cell and papillary serous cancer: treatment options. Baillieres. Best Pract Res Clin Obstet Gynecol 2001;15(3):433—46.
4. Hamilton C.A., Cheung M.K., Osann K. et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Brit J Cancer 2006;94:642—6.
5. Ульрих Е.А., Нейштадт Э.Л. Редкие формы рака тела матки. Практ онкол 2004;5(1):68—76.
6. Novak E. Gynecological and Obstetrical Pathology. Philadelphia, Sanders W.B.; 1947. p. 225—4.
7. Craighead P.S., Sait K., Gavin C.S. et al. Management of aggressive histolog- ic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994. Gynecol Oncol 2000;77:248—53.
8. Matthews R.P., Hutchinson-Colas J., Maiman M. et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol 1997;65:206—12.
9. Ульрих Е.А., Нейштадт Э.Л., Зельдович Д.Р., Урманчеева А.Ф. Комплексное лечение больных серозно-папиллярным раком. Материалы науч.-практ. конф., посвящ. 85-летию со дня основания ЦНИРРИ МЗ РФ. СПб.; 2003. с. 233—4.
10. Урманчеева А.Ф., Ульрих Е. А., Нейштадт Э.Л. и др. Серозно- папиллярный рак эндометрия (клинико-морфологические особенности. Вопр онкол 2002;48(6):679—83.
11. Halperin R., Zebavi S., Habler L. et al. Comparative immunohistochemical study of endometrioid and serous papil- lary carcinoma of endometrium. Eur J Gynecol Oncol 2001;22(2):122—6.
12. Slomovitz B.M., Burke T.W., Eifel P.J. et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003;91(3):463—9.
13. Hendrickson M., Ross J., Eifel P. et al. Uterine papillary carcinoma: a highly malignant from of endometrial adenocarcinoma. Am J Surg Pathol 1982;6(2):93—108.
14. Gallion H.H., Van Nagell J.R., Koborn E.I. et al. Stage I papillary carci- noma of endometrium. Cancer 1989;63:2224—8.
15. Scully R.E., Barlow J.F. Mesonephroma of ovary. Tumor of Mullerian nature related to the endometrioid carcinoma. Cancer 1967;20:1405—17.
16. Silverberg S., Kurman R. Tumours of the uterine corpus and gestational tro- phoblastic disease. Washington. Armed Forces Institute of Pathology; 1992. p. 240—88.
17. Abeler V.M., Vergote I.B., Kjorstad K.E. et al. Clear-cell carcinoma of the endometrium. Prognostic and metastatic pattern. Cancer 1996;78:1740—7.
18. Murphy K.T., Rotmensch J., Yamada S.D. et al. Outcome and patterns of failure in patologic stages I-IV clear- cell carcinoma of the endometrium: implications for adjuvant radiation thera- py. Int J Radiat Oncol Biol Phys 2003; 55(5):1272—6.
19. Clement P.B, Young R.H. Non-endometrioid carcinomas of the uterine corpus: a review of their patholo- gy with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2004;11:117—42.
20. Ross J.C., Eifel P.J., Cox R.S. et al. Primary mucinous adenocarcinoma of the endometrium. A clinicopathologic and histochemical study. Am J Surg Pathol 1983;7:715—29.
21. Dallenbach-Hellweg G., Hahn U. Mucinous and clear cell adenocarcino- mas of the endometrium in patients receiving antiestrogens (tamoxifen) and gestagens. Int J Gynecol Patol 1995;14:7—15.
22. Rodolakis A., Papaspyrou I., Sotiropoulou M. et al. Primary squamous cell carcinoma of the endometrium. A report of 3 cases. Eur J Gynaecol Oncol 2001;22:143—6.
23. Shidara Y. Karube A., Watanabe M. et al. A case report: verrucous carcinoma of the endometrium - the difficalty of diagnosis and a review of the literature. J Obstet Gynaecol Res 2000;26:189—92.
24. Kataoka A., Nishida T., Sugiyama T. et al. Squamous cell carcinoma of the endometrium with human papillomavirus type 31 and without tumor suppressor gene p53 mutation. Gynecol Oncol 1997;65:180—4.
25. Sherman M.E., Bitterman P., Rosenbein N.B. et al. Uterine papillary carcinoma. A morphologically disease neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992;16(6):600—10.
26. Carcangiu M.L., Cambers J.T. Uterine papillary serous carcinoma. A study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carci- noma. Gynecol Oncol 1992;47:298—305.
27. Goff B.A., Kato D., Schmidt R.A. et al. Uterine papillary serous carcinoma: Patterns of metastatic spread. Gynecol Oncol 1994;554:264—8.
28. Williams K.E., Waters E.D., Woolas R.P. et al. Mixed serous- endometrioid carcinoma of the uterus. Paphologic and cytopaphologic analysis of high-risk endometrial carcinoma. Int J Gynecol Cancer 1994;4:7—18.
29. Lim P., Al Kushi A, Gilks B. et al. Early stage uterine papillary serous carci- noma of the endometrium. Cancer 2001;91:752—7.
30. Wheeler D.T., Bell K.A., Kurman R.J. et al. Minimal uterine serous carcinoma. Am J Surg Pathol 2000;24:797—806.
31. Бохман Я.В. Руководство по онкогинекологии. Л., Медицина; 1989. с. 275—340.
32. Cirisano F.D., Robboy S.J., Dodge R.K. et al. The outcome of stage I-II clinically and surgically staged papil- lary serous and clear cell endometrial cancers when compared with endometri- oid carcinoma. Gynecol Oncol 2000;77:55—65.
33. Харитонова Т.В. Рак тела матки. Совр онкол 2000;2(2):4—10.
34. Erdem O., Erdem M., Dursun A. et al. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with tra- ditional clinicopatologic variables. Int J Gynecol Patol 2003;22:254—60.
35. Susini T., Amunni G., Molino C. et al. Ten-years results of prospective study on the prognostic role of ploidy in endometrial carcinoma. Cancer 2007;109(5):882—90.
36. Chan J.K., Lozzi V., Youssef M. et al. Significance of comprehensive sur- gical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol 2003;90:181—5.
37. Huh W.K., Powell M., Leath III C.A. et al. Uterine papillary serous carcinoma: comparisons of out- comes in surgical stage I patients with and without adjuvant therapy. Gynecol Oncol 2003;91:470—5.
38. Creasman W.T., Kohler M.F., Odicino F. et al. Prognosis of papillary serous, clear cell, and grade 3 stage I car- cinoma of the endometrium. Gynecol Oncol 2004;95:593—6.
39. Boruta D.M. 2nd, Gehrig P.A., Groben P.A. et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 2004;101:2214—21.
40. Khalifa M.A., Mannel R.S., Haraway S.D. et al. Expression of EGFR, Her-2/neu, P53 and PCNA in endometrioid, serous papillary and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994;53:84—92.
41. Athanassiadou P., Athanassiades P., Grapsa D. et al. The prognostic value of PTEN, p53 and β-catenin in endometrial carcinoma: a prospective immunocyto- chemical study. Int J Gynecol Cancer
42. ;17(3):697—704.
43. Alektiar V.M., McKee A., Lin O. et al. Is there a difference in outcome between stage I—II endometrial cancer of papillary serous/clear cell and endometri- oid FIGO Grade 3 cancer? Int J Radiat Oncol Biol Phys 2002;54:79—85.
44. Pradhan M., Abeler V.M., Danielsen H.E. et al. Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas. Mod Pathol 2006;19(9):1227—35.
45. Alkuchi A., Lim P., Coldman A. et al. Interpretation of p53 immunoreac- tivity in endometrial carcinoma: estab- lishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004;23(2): 129—37.
46. Osmanagaoglu M.A., Kadioglu S., Osmanagaoglu S. et al. The relationship between mutant p53gene, DNA contents and conventional clinicopatological prog- nostic variables in cases with endometrial carcinoma. Eur J Gynecol Oncol 2005;26(1):64—70.
47. Geisler J.P., Geisler H.E., Wiemann M.C. et al. P53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecol Oncol 1999;74(3):468—71.
48. Oreskovic S., Babic D., Kalafatic D. et al. A significance of immunohisto- chemical determination of steroid recep- tors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol 2004;93(1):34—40.
49. Kounelis S., Kapranos N., Kouri E. et al. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000;13(4):379—88.
50. Inaba F., Kawamata H., Teramoto T. et al. PTEN and p53 abnormalities are indicative and predicative factors for endometrial carcinoma. Oncol Rep 2005;13(1):17—24.
51. Wu H., Goel V., Haluska F.G. PTEN signaling pathways in melanoma. Oncogene 2003;22(20):3113—22.
52. Wijnhoven B.P., Dinjens W.N., Pignatelli M. E-cadherin-catenin cell- cell adhesion complex and human can- cer. Brit J Surg 2000;87(8):992—1005.
53. Stefansson I.M., Salvensen H.B., Akslen L.A. Prognostic impact of alter- ations in P-cadherin expression and related cell adhesion markers in endome- trial cancer. J Clin Oncol 2004;22: 1242—52.
54. Bremnes R.M., Veve R., Hirsch F.R. et al. The E-cadherin cell-cell adhesion complex and cancer invasion, metastasis, and prognosis. Lung Cancer 2002;36(2):115—24.
55. Kim Y.T., Choi E.K., Kim J.W. et al. Expression of E-cadherin and α-, β-, γ- catenin proteins in endometrial carcino- ma. Yonsei Med J 2002;43:701—11.
56. Matsui S., Shiozaki H., Inoue M. et al. Immunohistochemical evaluation of alpha-catenin expression in human gas- tric cancer. Virchows Arch 1994;424(4):375—81.
57. Jawhari A., Jordan S., Poole S. et al. Abnormal immunoreactivity of the E- cadherin-catenin complex in gastric car- cinoma: relationship with patient sur- vival. Gastroenterology 1997;112(1): 46—54.
58. Mell L.K., Meyer J.J., Tretiakova M. et al. Prognostic significance of E- cad- herin protein expression in pathological stage I—III endometrial cancer. Clin Cancer Res 2004;10:5546—53.
59. Sakuragi N., Nishiya M., Ikeda K. et al. Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol Oncol 1994;53:183—9.
60. Schlosshauer P.W., Ellenson L.N., Soslow R.A. Beta-catenin and E-cad- herin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol 2002;15(10):1032—7.
61. Tecimer C., Doering D.L., Coldsmith L.J. et al. Clinical relevance of urokinase-type plasmogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. Gynecol Oncol 2001;80(1):48—55.
62. Memarzadeh S., Kozak K.R., Chang L. et al. Urokinase plasminogen activator receptor. Prognostic biomarker for endometrial cancer. Proc Natl Acad Sci USA 2002;99(16):10647—52.
63. Karahan N., Guney M., Baspinar S. et al. Expression of gelatinase (MMP-2 and MMP-9) and cyclooxyge- nase-2 (COX-2) in endometrial carcino- ma. Eur J Gynecol Oncol 2007;28(3):184—8.
64. Lynch C.C., Matrisian L.M. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002;70(9-10):561—73.
65. Klapper L.N., Waterman H., Sela M. Tumor-inhibitory antibodies to Her-2/ErbB2 may act by recruiting c-Clb and enhancing ubiquitination of Her-2. Cancer Res 2000;60(13):3384—8.
66. Yu D., Hung M.C. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000;19:6115—21.
67. Coronado P.J., Vidart J.A., Lopez-asenjo J.A. et al. P53 overexpres- sion predicts endometrial carcinoma recurrence better than HER-2/neu over- expression. Eur J Obstet Gynecol Reprod Biol 2001;98(1):103—8.
68. Santin A.D., Bellone S., Gokden M. et al. Overexpression of Her-2/neu in uterine serous papillary cancer. Clin Cancer Res 2002;8:1271—9.
69. Geisinger K.R., Homesley H.D., Morgan T.M. Endometrial adenocarcino- ma: a multiparameter clinicopathologic analysis including the DNA profile and sex hormone receptors. Cancer 1986;58(7):1518—25.
70. Martin J.D., Hahnel R., McCartney A.J. The effect of estrogen receptor status on survival in patients with endometrial cancer. Am J Obstet Gynecol 1993;147(3):322—4.
71. Nyholm H., Christensen I.J., Nielsen A.L. Den prognostics betydning of progesteron receptoring hold ved endometrial cancer. Ugeskr Laeger 1997;159(5):601—4.
72. Palmer D.C., Muir I.M., Alexander A.I. The prognostic impor- tance of steroid receptors in endometrial carcinoma. Obstet Gynecol 1998;72(3):388—93.
73. Васильева Е.В., Белианин В.Л. Серозная аденокарцинома: критерии морфологического диагноза
74. и иммуногистохимия. Арх пат 2005;67(2):25—7.
75. Пожарисский К.М., Самсонова Е.А., Тен В.П. и др. Иммуногистохимический профиль эндометриоидной аденокарциномы тела матки: ER, PR, Her-2, Ki-67 и их прогностическое значение. Арх пат 2005;(2):13—7.
Рецензия
Для цитирования:
Лактионов К.П., Абдуллаева Г.М., Анурова О.А. КЛИНИКО-МОРФОЛОГИЧЕСКИЕ И МОЛЕКУЛЯРНО-БИОЛОГИЧЕСКИЕ ФАКТОРЫ ПРОГНОЗА РЕДКИХ ФОРМ РАКА ТЕЛА МАТКИ. Опухоли женской репродуктивной системы. 2008;(2):60-69. https://doi.org/10.17650/1994-4098-2008-0-2-60-69
For citation:
Laktionov K.P., Abdullayeva G.M., Anurova O.A. CLINICAL-MORPHOLOGIC AND MOLECULAR-BIOLOGIC PROGNOSTIC FACTORS FOR RARE FORMS OF UTERINE CANCER. Tumors of female reproductive system. 2008;(2):60-69. (In Russ.) https://doi.org/10.17650/1994-4098-2008-0-2-60-69